EUVIMEDEUVIMED entdecken
Crossref

Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats

Christopher N Subasic, Neville J Butcher, Rodney F Minchin iD, Lisa M Kaminskas iD

Molecular Pharmaceutics · 03.07.2023 · 20 (7) · 3494-3504

DOI: 10.1021/acs.molpharmaceut.3c00104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 31.05.2023. Verfasst von Christopher N Subasic und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, University of Queensland, St Lucia, QLD 4072, Australia. Hauptthemen laut MEDLINE: COVID-19, Nanoparticles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Health and Medical Research Council, University of Queensland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PEGylated lipid nanoparticle-based Covid-19 vaccines, including Pfizer's BNT162b2 and Moderna's mRNA-1273, have been shown to stimulate variable anti-PEG antibody production in humans. Anti-PEG antibodies have the potential to accelerate the plasma clearance of PEGylated therapeutics, such as PEGylated liposomes and proteins, and compromise their therapeutic efficacy. However, it is not yet clear whether antibody titers produced by PEGylated Covid-19 vaccines significantly affect the clearance of PEGylated therapeutics. This study examined how anti-PEG IgM levels affect the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) and compared the immunogenicity of a lipid nanoparticle formulation of linear DNA (DNA-LNP) to standard PEG-HSPC liposomes. DNA-LNP was prepared using the same composition and approach as Pfizer's BNT162b2, except linear double-stranded DNA was used as the genetic material. PEGylated HSPC-based liposomes were formulated using the lipid rehydration and extrusion method. Nanoparticles were dosed IM to rats at 0.005-0.5 mg lipid/kg body weight 1 week before evaluating the plasma pharmacokinetics of clinically relevant doses of PLD (1 mg/kg, IV) or PEGylated interferon α2a (Pegasys, 5 μg/kg, SC). Plasma PEG IgM was compared between pre- and 1-week post-dose blood samples. The results showed that anti-PEG IgM production increased with increasing PEG-HSPC liposome dose and that IgM significantly correlated with the plasma half-life, clearance, volume of distribution, and area under the curve of a subsequent dose of PLD. The plasma exposure of Pegasys was also significantly reduced after initial delivery of 0.005 mg/ml PEG-HSPC liposome. However, a single 0.05 mg/kg IM dose of DNA-LNP did not significantly elevate PEG IgM and did not alter the IV pharmacokinetics of PLD. These data showed that PEGylated Covid-19 vaccines are less immunogenic compared to standard PEGylated HSPC liposomes and that there is an antibody threshold for accelerating the clearance of PEGylated therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NanoparticlesRatsHumansAnimalsLiposomesBNT162 VaccineCOVID-19 VaccinesImmunoglobulin MPolyethylene GlycolsDNAPhosphatidylcholinesDoxorubicin

Stichwörter der Autor:innen

Covid-19accelerated blood clearanceanti-PEG IgMliposomepharmacokineticspoly(ethylene glycol)

Substanzen

LiposomesBNT162 VaccineCOVID-19 VaccinesImmunoglobulin MPolyethylene GlycolsDNAPhosphatidylcholinesliposomal doxorubicinDoxorubicin

Autor:innen und Institutionen

  • School of Biomedical Sciences, University of Queensland, St Lucia, QLD 4072, Australia.

ORCID-Profile: Rodney F Minchin, Lisa M Kaminskas

Förderung

  • National Health and Medical Research Council
  • University of Queensland

Zitieren

APA

Subasic, C. N., Butcher, N. J., Minchin, R. F., & Kaminskas, L. M. (2023). Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats. Molecular Pharmaceutics, 20(7), 3494-3504. https://doi.org/10.1021/acs.molpharmaceut.3c00104

Vancouver

Subasic CN, Butcher NJ, Minchin RF, Kaminskas LM. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats. Molecular Pharmaceutics. 2023;20(7):3494-3504. doi:10.1021/acs.molpharmaceut.3c00104

BibTeX
@article{Subasic2023,
  author = {Subasic, Christopher N and Butcher, Neville J and Minchin, Rodney F and Kaminskas, Lisa M},
  title = {Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  volume = {20},
  number = {7},
  pages = {3494--3504},
  doi = {10.1021/acs.molpharmaceut.3c00104}
}
Kostenlos starten →